Brokers Offer Predictions for Cresco Labs Q1 Earnings

Cresco Labs Inc. (OTCMKTS:CRLBF - Free Report) - Analysts at Ventum Cap Mkts issued their Q1 2025 earnings estimates for Cresco Labs in a report issued on Wednesday, March 12th. Ventum Cap Mkts analyst A. Semple expects that the company will earn ($0.03) per share for the quarter. The consensus estimate for Cresco Labs' current full-year earnings is ($0.20) per share. Ventum Cap Mkts also issued estimates for Cresco Labs' Q2 2025 earnings at ($0.03) EPS, Q3 2025 earnings at ($0.02) EPS and Q4 2025 earnings at ($0.02) EPS.

Cresco Labs (OTCMKTS:CRLBF - Get Free Report) last released its quarterly earnings results on Friday, March 14th. The company reported ($0.01) earnings per share for the quarter, hitting the consensus estimate of ($0.01). Cresco Labs had a negative net margin of 9.15% and a negative return on equity of 16.52%. The business had revenue of $176.00 million for the quarter, compared to the consensus estimate of $172.10 million.

Other equities analysts have also issued research reports about the stock. Cormark upgraded shares of Cresco Labs from a "hold" rating to a "moderate buy" rating in a research report on Monday. Atb Cap Markets lowered shares of Cresco Labs from a "strong-buy" rating to a "hold" rating in a report on Monday, December 9th. Two equities research analysts have rated the stock with a hold rating, one has given a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Cresco Labs has an average rating of "Buy" and an average price target of $3.00.

Remove Ads

Cresco Labs Price Performance

Shares of OTCMKTS CRLBF traded down $0.03 during midday trading on Friday, reaching $0.71. The stock had a trading volume of 319,620 shares, compared to its average volume of 590,347. The stock has a 50-day moving average of $0.88 and a 200-day moving average of $1.19. The company has a debt-to-equity ratio of 1.80, a quick ratio of 1.39 and a current ratio of 1.97. The company has a market capitalization of $344.14 million, a price-to-earnings ratio of -3.53 and a beta of 1.79. Cresco Labs has a 12-month low of $0.70 and a 12-month high of $2.60.

Cresco Labs Company Profile

Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.